Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary | Agenda Bookshop Skip to content
Selected Colleen Hoover Books at €9.99c | In-store & Online
Selected Colleen Hoover Books at €9.99c | In-store & Online
A01=Board on Health Care Services
A01=Institute of Medicine
A01=National Cancer Policy Forum
Age Group_Uncategorized
Age Group_Uncategorized
Author_Board on Health Care Services
Author_Institute of Medicine
Author_National Cancer Policy Forum
automatic-update
B01=Erin Balogh
B01=Margie Patlak
B01=Sharyl J. Nass
Category1=Non-Fiction
Category=MBGR
Category=MJCL
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=Available
Price_€20 to €50
PS=Active
softlaunch

Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary

Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation.

Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development. While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations.

Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings.

Table of Contents
  • Front Matter
  • Workshop Summary
  • Acronyms
  • Glossary
  • Appendix A: Workshop Agenda
  • Appendix B: Polling Results
See more
Current price €41.79
Original price €43.99
Save 5%
A01=Board on Health Care ServicesA01=Institute of MedicineA01=National Cancer Policy ForumAge Group_UncategorizedAuthor_Board on Health Care ServicesAuthor_Institute of MedicineAuthor_National Cancer Policy Forumautomatic-updateB01=Erin BaloghB01=Margie PatlakB01=Sharyl J. NassCategory1=Non-FictionCategory=MBGRCategory=MJCLCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=AvailablePrice_€20 to €50PS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Dimensions: 152 x 229mm
  • Publication Date: 15 Oct 2010
  • Publisher: National Academies Press
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9780309156547

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept